Verlingue Strengthens Its Position in Europe by Gaining a Foothold in Italy With the Acquisition From ISA of a Majority Stake in INSER
12.7.2023 11:33:00 EEST | Business Wire | Press release
Verlingue announces the acquisition of a majority stake in the insurance broker INSER, in line with its Verlingue 2024 strategic plan to create a major European, family-owned, independent insurance broker. This move to acquire a stake in the Italian market consolidates this ambition:
- Verlingue has chosen Italy as its fifth country of operations after France, the UK, Switzerland and Portugal.
- INSER is Verlingue's 7th international acquisition in 7 years
- Verlingue has become a majority shareholder in the Italian broker INSER, one of Italy's leading independent brokers
- The long-standing shareholder, ISA, remains a minority shareholder in INSER to continue to support its growth in Italy
- 160 INSER employees are joining Verlingue, whose international turnover now accounts for 35% of its total turnover.
Founded in 1979 in Trento, INSER is one of the leading independent players in the Italian insurance brokerage market. It focuses on corporate risks and public procurement. The Italian broker, which has expanded through targeted organic growth and a strategic acquisitions programme, employs nearly 160 staff in 8 offices in northern Italy (Trento, Parma, Brescia, Milan, Bergamo, Vicenza, Udine) and central Italy (Rieti).
With Italy, Verlingue is entering an important strategic market by making its seventh acquisition outside France in seven years, following on from its acquisitions in Switzerland (2016, 2017 and 2019), the UK (2018) and Portugal (2020, 2022).
With this new acquisition, the Adelaïde Group continues to execute its 2024 strategic plan with the ambition of becoming a major European, family-owned, independent insurance broker, serving increasingly international customers. Verlingue's ambition in Italy is to become a benchmark broker in the market for SMEs, mid-caps, large companies and public authorities. Verlingue will be able to rely on the current management team.
Under the terms of the partnership, Verlingue will become INSER's majority shareholder, while its long-standing shareholder, ISA, will retain a minority stake and continue to support its growth in Italy.
Giorgio Franceschi, Deputy Chairman of ISA, said: “We are delighted with this acquisition. We have found a solid and credible international partner in the family-owned Verlingue group, which will now contribute to a new phase in the development of INSER, a long-standing and important subsidiary of ISA, which we have supported in its growth and in which we will continue to be present. The partnership between Verlingue and ISA offers a great opportunity to create value for customers, employees and the region as a whole.”
Regarding the partnership, Pierpaolo Ruggeri, CEO of Inser Spa, said: “Verlingue's European project is exciting and Italy is a strategic country. This partnership will enable us to strengthen our development trajectory, both through organic growth and targeted acquisitions, in order to consolidate our positioning and offer a high-quality service to our customers.”
Benjamin Verlingue, Deputy CEO of the Adelaïde Group: “I am delighted that Adelaïde is setting up operations in Italy, Europe's fourth-largest insurance market. This opens up many positive prospects for our customers, who are becoming increasingly international.
In an industry that is consolidating, being a family-run broker with an ambitious, long-term vision means that we can offer an appealing plan to the teams who decide to join us. I'm very pleased that Inser and ISA made this choice.”
Anne-Jacques de Dinechin, Chief Executive Officer of Verlingue, said: “Our international success is based on strong local management teams in each country. With the acquisition of Inser, we are bringing on board a team of committed experts who will play a full part in our goal to become a major player in Europe.”
About Verlingue
An insurance broker specialising in business protection, Verlingue is a subsidiary of the Adelaïde Group.
Working alongside entrepreneurs, Verlingue’s goal is to harness corporate risk management and employee protection to drive its customers’ value creation and performance.
With offices in France, Portugal, Switzerland, Great Britain and Italy, and through partners in over 100 countries, Verlingue works with its customers over the long term and at all times to better understand and plan ahead for new risks in order to develop simple yet effective solutions to protect their business (corporate risk) and staff (supplementary social protection schemes and pensions).
1,350 employees, 550 of whom are based outside France
€2,350m in premiums negotiated on behalf of its customers
Operating out of 5 countries in Europe
LinkedIn/www.verlingue.fr
About Inser
Leading insurance broker providing protection for companies and public bodies. With over 40 years of experience in Italy, INSER is able to meet the specific needs of each of its customers with a team of employees capable of developing personalised solutions with the utmost care and professionalism. With 8 offices in Italy, INSER has a strong regional presence, ensuring that it is close to its customers and therefore able to generate value.
160 employees
€130m in premiums negotiated on behalf of its customers
8 locations
LinkedIn/www.inserspa.eu
About ISA
Istituto Atesino di Sviluppo Spa (ISA) is a holding company that has been operating in Trentino-Alto Adige and neighbouring regions for over 90 years. ISA's aim is to acquire stakes, mainly minority ones, by investing in diversified initiatives with the role of a patient long-term partner, with a view to creating value. Investments are selected with the utmost care and rigour, with a view to creating a sustainable development path that is attentive to social and economic growth. Through an effective network of contacts, ISA brings together private capital and financial institutions, generating opportunities for investment, growth and development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711157642/en/
Contact information
Press contact
Adelaïde Group – Thomas Barbelet – thomas.barbelet@verlingue.fr – +33(0)6 72 75 49 14
Epoka Agency – Lucie Fortin – lfortin@epoka.fr – +33(0)6 19 68 70 18
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 15:02:00 EEST | Press release
Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty Texture Editwas designed to resonate with a global cultural beauty movement captivating the next gene
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 15:00:00 EEST | Press release
GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005273717/en/ SOFIE Biosciences has 15 CMO sites across the U.S., manufacturing PET radiopharmaceutical products The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics
Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 14:24:00 EEST | Press release
Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking expertise with Solos' proprietary dealcoholization and patented aroma recovery technology. With 30 years of experience in producing alcohol-free sparkling wines, Henkell Fre
Croma-Pharma Expands Its Portfolio in Canada With saypha ® lips Lidocaine and Exprecell™5.10.2026 14:12:00 EEST | Press release
Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia
Anaeco Secures Strategic Investment from Momentum Global Ventures to Accelerate Commercial Deployment5.10.2026 13:00:00 EEST | Press release
Anaeco, Inc., a clean technology company developing systems to destroy harmful and difficult-to-abate gases, today announced a strategic investment from Momentum Global Ventures. The investment supports Anaeco as it moves from technology development and validation to commercial deployment across three initial markets: anesthetic gases, refrigerants, and semiconductor manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005546122/en/ Anaeco’s technology exploits atmospheric chemistry to destroy harmful, high-impact gases, including HFCs, PFAS, anesthetic gases, N2O, and other difficult-to-abate emissions at their source. By accelerating processes that naturally transform pollutants, its modular technology provides a practical, scalable approach to emissions that are difficult or costly to manage conventionally. Initial Commercial Verticals Anesthetics: Destroying anesthetic gases generated in healthcare environmen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
